<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756067</url>
  </required_header>
  <id_info>
    <org_study_id>111652</org_study_id>
    <nct_id>NCT00756067</nct_id>
  </id_info>
  <brief_title>Evaluation of Pneumococcal Vaccine Formulations in Elderly</brief_title>
  <official_title>A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189241A) in Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to evaluate the safety, reactogenicity and
      immunogenicity of pneumococcal vaccines in elderly. Subjects will be vaccinated twice with an
      interval of two months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2008</start_date>
  <completion_date type="Actual">May 28, 2009</completion_date>
  <primary_completion_date type="Actual">May 28, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of any vaccine related and grade 3 solicited local and general adverse events</measure>
    <time_frame>During a 7-day follow up period after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any vaccine related and grade 3 unsolicited adverse events</measure>
    <time_frame>During a 31-day follow up period after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any vaccine related serious adverse events (SAE)</measure>
    <time_frame>From dose 1 to study conclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any grade 3 laboratory abnormalities</measure>
    <time_frame>At 1 and 7 days after each vaccine dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any solicited local and general adverse events</measure>
    <time_frame>During a 7-day follow up period after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any unsolicited adverse events</measure>
    <time_frame>During a 31-day follow up period after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any laboratory abnormalities</measure>
    <time_frame>At 1 and 7 days after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any medically significant conditions prompting emergency room visits or physician visits regardless of casual relationship to vaccination or intensity</measure>
    <time_frame>From dose 1 to study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-pneumococcal and anti-NTHi candidate vaccine antigens</measure>
    <time_frame>At Days 0, 30 and 90</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>23 valent pneumococcal vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2189241A</intervention_name>
    <description>Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.</description>
    <arm_group_label>Formulation 4</arm_group_label>
    <arm_group_label>Formulation 5</arm_group_label>
    <arm_group_label>Formulation 2</arm_group_label>
    <arm_group_label>Formulation 3</arm_group_label>
    <arm_group_label>Formulation 6</arm_group_label>
    <arm_group_label>Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumo 23™</intervention_name>
    <description>One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.</description>
    <arm_group_label>23 valent pneumococcal vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes will comply with the requirements of the
             protocol should be enrolled in the study.

          -  Male or female subjects between, and including, 65 and 85 years old at the time of the
             first vaccination, in relatively stable health.

          -  Written informed consent obtained from the subject.

        Exclusion Criteria:

          -  Previous vaccination against Streptococcus pneumoniae (with a licensed vaccine or with
             an investigational candidate vaccine).

          -  Vaccination with diphtheria/tetanus toxoids within one month preceding the first dose
             of study vaccine.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period or participation to another pharmaceutical/vaccine study.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days of the first dose of study vaccine, with the exception of the influenza
             vaccine which can be administered at least 7 days preceding or at least 7 days
             following any vaccine dose.

          -  Administration of immunoglobulins and/or any blood products within the last 3 months.

          -  Bacterial pneumonia within 3 years prior to 1st vaccination.

          -  Invasive pneumococcal disease (I.P.D) within 3 years prior to 1st vaccination.

          -  History of thrombocytopenia or bleeding disorder.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  History of reactions or allergic disease likely to be exacerbated by any component of
             the vaccine.

          -  History of administration of an experimental/licensed vaccine containing MPL or QS21.

          -  Current serious neurologic or mental disorders.

          -  Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).

          -  All past or current malignancies (excluding non-melanic skin cancer) and
             lymphoproliferative disorders diagnosed or treated actively during the past 5 years.

          -  Acute disease at the time of enrolment.

          -  Physical examination positive for acrocyanosis, jaundice, splenomegaly

          -  Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hepatic
             or renal functional abnormality, as determined by history, physical examination or
             laboratory screening tests at the discretion of the investigator.

          -  Laboratory evidence of haematological abnormalities.

          -  Laboratory evidence of biochemical abnormalities.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Other conditions that the principal investigator judges may interfere with study
             findings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/111652?search=study&amp;b%22b''%22#rs</url>
    <description>Results for study 111652 can be found on the GSK Clinical Study Register</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>pneumococcal vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111652</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111652</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111652</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111652</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111652</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

